 After the FDAs approval of Tzield and with better-than-expected pricing, we are upgrading to a Buy rating. PRVBs pricing and approval bode well for the stock and de-risk owning it; however, we are neutral around the Q1-Q2 sales print due to uncertainty around market access. 